Recent Tweets Page 94

Q: How does CV risk cp to Leuk risk? Bolton #NGDx18 Lower but so prevalent, the absolute rates are higher

9:20am August 23rd 2018 via Twitter Web Client

Bolton #NGDx18 Also ped cancer survivors - high-dose radiation can observe high-risk CH.

9:18am August 23rd 2018 via Twitter Web Client

Bolton #NGDx18 36F met Ov ca, stable on carboplatin, prog cytopenia, TP53 mut. Launched a CH clinic, for either CVD or Leuk risk

9:15am August 23rd 2018 via Twitter Web Client

Bolton #NGDx18 A case - 72F w/new Dx of br ca, TP53 CH mutation. AZT, radiation, has a risk of CVD as survivor

9:13am August 23rd 2018 via Twitter Web Client

Bolton #NGDx18 Not only coronary artery disease but also stroke. Also shows data on mutations in skin of normal individuals

9:06am August 23rd 2018 via Twitter Web Client

Bolton #NGDx18 The driver genes are in leukemia, myeloid genes. Abs risk is low - 0.5%/year, reduced mortality. CH w/CV disease

9:03am August 23rd 2018 via Twitter Web Client

Kelly Bolton (MSKCC) #NGDx18 The impact of oncologic therapy on the risk of clonal hematopoeisis and subsequent hematologic malignancy

9:00am August 23rd 2018 via Twitter Web Client

Q: Could it be CTCs confounding? Zehir #NGDx18 Definitely looking at it.

8:58am August 23rd 2018 via Twitter Web Client

Zehir #NGDx18 CH observed in 25% of adv cancer, can confound tumor-only seq in 5% of population.

8:56am August 23rd 2018 via Twitter Web Client

Zehir #NGDx18 ID of CH variants in cfDNA a VAF 1% for DNMT3A, but VAF 3% in buffy coat so it is CH.

8:55am August 23rd 2018 via Twitter Web Client

Zehir #NGDx18 Can confound NSCLC cfDNA results '18 ref https://t.co/zSj1xjsPLw

8:49am August 23rd 2018 via Twitter Web Client

Zehir #NGDx18 'Ubiquitous' when looking with a sensitive sequencing approach (MSK-IMPACT, namely) '16 ref https://t.co/p8bijfnMBS

8:41am August 23rd 2018 via Twitter Web Client

Zehir #NGDx18 In cancer pts - 24%, 'CH is common and assoc'd with adverse outcomes' '17 ref https://t.co/rreaWCavkm

8:40am August 23rd 2018 via Twitter Web Client

Zehire #NGDx18 There is allelic pressure for certain clones to grow. A fn of age: '14 NEJM https://t.co/xfZMQNucEK and increased risk of CVD

8:38am August 23rd 2018 via Twitter Web Client

Zehir #NGDx18 Dep on the gene, can lead to full-blown leukemia '16 NEJM https://t.co/e0JYsEAGsT

8:37am August 23rd 2018 via Twitter Web Client

Ahmet Zehir (MSKCC) #NGDx18 Clonal hematopoeisis (CH) is common in cancer patients and can confound clinical genomic profiling

8:36am August 23rd 2018 via Twitter Web Client

Luis Diaz (MSKCC) Introductory remarks. #NGDx18 Clonal hematopoeisis is an entity, how to test / apply to end-pt.

8:35am August 23rd 2018 via Twitter Web Client

This ancient bone belonged to a child of two extinct human species | Science Magazine https://t.co/aMd0UNJxrn

8:25pm August 22nd 2018 via Hootsuite Inc.

Bionano Genomics Raises $20.6M in IPO, Starts Trading on Nasdaq | GenomeWeb https://t.co/yrNuDDdNWs

6:50pm August 22nd 2018 via Hootsuite Inc.

Benayed #NGDx18 They preferentially select low TMB samples for RNA-Seq. 14% MSK-Fusion Pos. 80% of these show clinical benefit.

4:58pm August 22nd 2018 via Twitter Web Client

Benayed #NGDx18 LOXO NTRK ref '18 https://t.co/Qlowi6Yuk5 Describes MSK-IMPACT 70 introns of 20 re-arr genes.

4:41pm August 22nd 2018 via Twitter Web Client

Benayed #NGDx18 Also therapeutic: targetable for TKIs '17 revihttps://www.ncbi.nlm.nih.gov/pubmed/28857077 LOXO-101 for TRK

4:39pm August 22nd 2018 via Twitter Web Client

Benayed #NGDx18 Gene fusions can be diagnostic (TEMPRSS2-ERG for prostate ca) and prognostic (RBM10-TFE2 for renal cell carcinoma)

4:38pm August 22nd 2018 via Twitter Web Client

Ryma Benayed (MSKCC) #NGDx18 Comprehensive DNA and RNA profiling in solid tumors for the detection of targetable kinase fusions

4:36pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 ASCO Review - ctDNA 'not yet' but on the horizon. '18 review https://t.co/M5E41mWFfd

2:36pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 ctDNA detection prognostic for I-O Rx in melanoma '17 ref https://t.co/MM42z6j1Wy PFS by ctDNA profile

2:33pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 Is there a compound or activity (tissue trauma) that would increase conc. of ctDNA in sample?

2:30pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 FFPE heterogeneity - they sample from may parts of the tissue. ctDNA in plasma increases after prostatectomy or DRE in CRC

2:29pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 5K samples, prevalence by day of testing, rates changed for ER testing '10 ref https://t.co/34fnD2Tp5M

2:26pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 Another study comparing PIK3CA status using BEAMing https://t.co/ZaNv5vP81b

2:25pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 Shows Supp Table 6 from '17 ref https://t.co/ZQSJLu4BRO PIK3CA status in tumor and ctDNA, comparing Sanger tissue to ctDNA

2:24pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 Herceptin - high PPA, NPA, stand-alone. If not high, then reflex.

2:22pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 37 approved CDx assays; 1 for ctDNA. Herceptin has 10 approved assays. Concordance.

2:17pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 Shows publication explosion in ctDNA, 649 papers in '17. BloodPAC for sharing information between stakeholders.

2:15pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 Another con: ave result of all ctDNA cannot differentiate somatic from germline, CHIP, or clonal var

2:14pm August 22nd 2018 via Twitter Web Client

Beer #NGDx18 Late-stage disease, get liquid biopsy. Pros: easily obtained, no crosslinking, 2h half-life, lower risk of sampling bias

2:11pm August 22nd 2018 via Twitter Web Client